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STATISTICAL GENETIC ANALYSES OF LARGE JOINT OA
A.M. Valdes
King’s Coll. London, London, United Kingdom
Purpose: Severe large joint osteoarthritis (OA (hip and knee) is a major
cause of and its prevalence is expected to climb as the age of the population
increases. OA is a multifactorial disease and OA cases are affected by both
genetics and environment to varying degrees. Understanding the genetic
component of OA can help uncover its molecular pathogenesis.
Methods: A review of the literature on methods which have been used to
explore the genetic contribution to large joint OA with particular emphasis
on association studies
Results: Strong familial aggregation and heritabilities have been reported
for OA at the hip, and the knee. From linkage analyses to current genome-
wide association scans a number of approaches have been used in past
decade to try to unravel the genetic component of large joint OA. Candidate
gene studies and genome-wide linkage studies have identiﬁed genes in the
bone morphogenetic pathway (GDF5 and SMAD3), the thyroid regulation
pathway (DIO2), and cell-death related pathways as involved in genetic risk
of large joint OA. Genome wide association studies have reported structural
genes (COL6A4/DVWA), inﬂammation related genes (PTGS2/PLA2G4A) and
a locus chr 7q22 associated with knee OA and two genes in the HLA
class II and class III regions (DQB1 and BTNL2). The challenges involved
in the statistical analysis of genetic data with speciﬁc emphasis on the
heterogeneity of large OA phenotypes and approaches to subphenotyping
are discussed.
Conclusions: During the coming years, as additional genetic and functional
studies further deﬁne the genetic architecture of OA and the underlying
molecular mechanisms, additional targets for novel therapies and improved
diagnostic and prognostic tests should be identiﬁed.
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The hand represents a particularly useful structure for imaging OA for
many reasons including the genetic association with generalised nodal OA
and hand disease, the relatively fast onset of hand OA, especially in the
peri-menopausal period and the ability to clinically recognise disease when
conventional radiography is normal. We have used high resolution MRI to
explore early clinically evident hand OA and age related changes in the
hands in normals and also an assessment of clinically uninvolved joints
in cases with OA elsewhere. This work has been combined with cadav-
eric tissues studies to deﬁne the microanatomical basis for the observed
changes.
Whilst end stage hand OA is a disease of the whole joint it is evident that
the earliest and most striking changes are evident in the joint collateral lig-
aments in particular but also in joint capsules and tendons. These changes
including thickening, inﬂammatory changes and even complete ligament
disruption. On MRI most hand OA is erosive with these erosions being
topographically related to collateral ligaments. Likewise the position of
ligaments has been conﬁrmed as key players in the phenotypic expression
of Heberdens nodes. Prominent bone oedema at entheses is a common
feature of early hand OA and it can actually be diﬃcult to distinguish
this pattern of disease from psoriatic arthritis which is more commonly
recognised to be associated with enthesitis.
The inﬂammatory changes associated with hand OA are extensive on MRI
and appear to be centred on the capsule and extracapsular tissues to a
greater degree than the synovium. This challenges the classical view of
articular cartilage damage as the major driver in synovitis in OA. These MRI
features have been used to deﬁne a novel enthesis related joint structure
termed the synovio-entheseal complex which shows all of the histologoical
changes of OA and appears to be a ligament related mechanism of driving
synovitis in hand OA.
To date high resolution MRI imaging has permitted the conceptualisation
of a new anatomical classiﬁcation for OA based on the fact much idiopathic
hand OA is not idiopathic, at least from the anatomical site of maximal
early disease changes. The prognostic value of both MRI and ultrasound
needs to be determined in follow us studies.
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ARE GWAS STUDIES FOR OSTEOARTHRITISWORTH THE EXPENSE?
M. Warman
Children’s Hosp. Boston, Boston, MA
Forty years ago, blood group polymorphisms and other protein polymor-
phisms were the major means available to link a disease phenotype to a
gene. Thirty years ago, restriction fragment length polymorphisms detected
by Southern blotting ushered in a new era of DNA-based genetic analysis.
Twenty years ago, simple-sequence-repeat polymorphisms detected by PCR
made it possible to begin mapping hundreds of human Mendelian-genetic
diseases at reasonable cost. This PCR-based mapping coupled with the
$2,700,000,000 (U.S. taxpayer cost) Human Genome Project has culminated
in the discovery of many genes that cause human genetic disease. Over
the past decade, high-density nucleic acid array technologies have created
a new paradigm for disease-gene identiﬁcation and have provided oppor-
tunities to extend genetic analyses from patients affected with Mendelian
traits to patients affected with multifactorial diseases, such as diabetes,
obesity, mental illness, and rheumatoid arthritis. These advances are based
on the ability, in a single person and at reasonable cost, to simultaneously
query 1,000,000 common DNA variants (SNPs) distributed evenly across the
human genome. It is now reasonable to ask whether this new technology
should be applied to the study of osteoarthritis.
What have we learned from GWAS studies in other diseases? For age-
related macular degeneration and statin-induce myopathy, using fewer
than 100 cases and 100 controls, we learned that common population
variants in C3H and SLCO1B1, respectively, are strong genetic risk factors.
In contrast, for blood lipid proﬁles and for height, using greater than
100,000 participants, we learned that dozens of common variants, each
having modest to minimal effects, account for less then 25% of the genetic
variance. A priori, it was not known whether common diseases would
be inﬂuenced by few genes each with large effects, or by many genes
each with small effects. To date, most common diseases studied using
GWAS appear to fall into the latter category. Nevertheless, GWAS has
identiﬁed novel genes and pathways involved in disease processes, even
when the effect size of the common variant is small, just as rare Mendelian
genetic disorders have led to the discovery of genes and pathways whose
disease-causing variants are rare but have large effects.
Several questions are worth pondering when deciding whether GWAS
studies for OA are worth the expense. How easy is it to diagnose and
quantify osteoarthritis, compared to other complex traits? How much of
the population variance for OA is genetic? Is the genetic architecture of
OA likely to be due to a few common variants of moderate effect or
many common variants of weak effect? Is the discovery of new genes and
pathways suﬃcient reward for the expense of a GWAS study, or must
these new discoveries be “actionable,” in that they immediately improve
diagnosis or suggest new therapeutic strategies? Currently sequencing
the entire genome of an individual is twenty-times more expensive than
genotyping that individual for 1,000,000 SNPs. Therefore, for $10,000,000
is it better to perform whole genome sequencing on 1000 patients with OA
or to perform GWAS in 10,000 OA patients and 10,000 controls? We could
simply wait for sequencing costs to fall. But is the cost of waiting and not
discovering anything new greater than the cost of performing GWAS or
limited whole exome or whole genome sequencing now?
